Summary. We have treated 17 refractory or relapsed multiple myeloma patients resistant to chemotherapy with thalidomide at a dose of 200±800 mg/day. Eleven patients responded, ®ve of whom had a very good partial response (> 75% decline in M protein) and another ®ve exhibited a partial response (> 50% decline in M protein). Except for one patient, treatment was well tolerated with only mild sideeffects. Thalidomide should be included in the therapeutic options for refractory myeloma.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.